RxDoctor Payments Data

Jose Zaglul, MD

Psychiatry · Bradenton, FLNPI 1225024763

Payments from drug & device makers

$111,510in general payments, 2019–2025

Across 127 payments — averaging $878.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$82K
  • AbbVie$15K
  • Teva Pharmaceuticals USA, Inc.$6K
  • Rhodes Pharmaceuticals L.p.$4K
  • Boehringer Ingelheim$3K
  • Neurocrine Biosciences, Inc.$720
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$7,99475%
  • Food & beverage$2,56124%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,510 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$49,739
Medicare patients
115
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine15$85,832
Invega SustennaPaliperidone Palmitate20$63,365
Risperdal ConstaRisperidone Microspheres13$36,439
RexultiBrexpiprazole13$21,302
Aripiprazole77$6,281
Olanzapine105$5,135
Fluphenazine Hcl26$4,753
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$4,499
Divalproex Sodium ErDivalproex Sodium39$2,612
Haloperidol Decanoate48$2,563
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine63$2,320
Donepezil Hcl13$2,119
Duloxetine Hcl69$1,858
Clonazepam140$1,806
Quetiapine Fumarate50$1,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$267$99,80433 claims
Teva Pharmaceuticals USA, Inc.Austedo$5,581$85,83215 claims
Otsuka America Pharmaceutical, Inc.Rexulti$58$21,30213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →